Geoff Meacham Analyst Performance

Managing Director / Global Head of Healthcare at Citigroup

Geoff Meacham is a stock analyst at Citigroup, covering 42 publicly traded companies across a range of sectors. Over the past year, Geoff Meacham has issued 32 stock ratings, including buy, hold, and sell recommendations. While full access to Geoff Meacham's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Geoff Meacham's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 97 Last 10 Years
Buy Recommendations: 64.95% 63 Buy Ratings
Companies Covered: 42 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	64.9%	63 ratings
Hold	27.8%	27 ratings
Sell	7.2%	6 ratings

Out of 97 total stock ratings issued by Geoff Meacham at Citigroup, the majority (64.9%) have been Buy recommendations, followed by 27.8% Hold and 7.2% Sell.

Best & Worst Calls

Best Call
000.0%
PTCT
Mar 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
MDVN
Feb 2015
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	88.1% of companies on NASDAQ	37 companies
NYSE	11.9% of companies on NYSE	5 companies

Geoff Meacham, an analyst at Citigroup, currently covers 42 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 40 companies	95.2%
	Miscellaneous 2 companies	4.8%

Geoff Meacham of Citigroup specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 25 companies	59.5%
MED - DRUGS 6 companies	14.3%
LARGE CAP PHARMA 4 companies	9.5%
PHARMACEUTICAL PREPARATIONS 4 companies	9.5%
Miscellaneous 2 companies	4.8%
MED - GENERIC DRG 1 company	2.4%

Time Frame

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
AMLX Amylyx Pharmaceuticals	8/28/2025	Boost Price Target	$9.47	$14.00	Buy
VIR Vir Biotechnology	8/27/2025	Upgrade	$4.44	$14.00	Buy
ABOS Acumen Pharmaceuticals	8/25/2025	Lower Price Target	$1.51	$9.00	Buy
AMGN Amgen	8/6/2025	Boost Price Target	$284.67	$310.00	Neutral
REGN Regeneron Pharmaceuticals	8/1/2025	Reiterated Rating	$545.46	$650.00	Buy
MRNA Moderna	8/1/2025	Initiated Coverage	$29.56	$40.00	Neutral
BIIB Biogen	8/1/2025	Boost Price Target	$131.95	$135.00	Neutral
PTCT PTC Therapeutics	7/28/2025	Boost Price Target	$44.96	$50.00	Neutral
RPRX Royalty Pharma	7/22/2025	Boost Price Target	$35.64	$42.00	Buy
AMGN Amgen	7/22/2025	Boost Price Target	$302.13	$305.00	Neutral
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
CRSP CRISPR Therapeutics	7/22/2025	Lower Price Target	$64.51	$78.00	Buy
BBIO BridgeBio Pharma	6/25/2025	Boost Price Target	$44.79	$54.00	Buy
ACLX Arcellx	6/17/2025	Initiated Coverage	$64.09	$110.00	Buy
AMLX Amylyx Pharmaceuticals	6/17/2025	Initiated Coverage	$5.44	$12.00	Buy
ABOS Acumen Pharmaceuticals	6/17/2025	Initiated Coverage	$1.14	$4.00	Buy
NVAX Novavax	6/17/2025	Initiated Coverage	$7.03	$6.00	Sell
PTGX Protagonist Therapeutics	6/17/2025	Initiated Coverage	$54.66	$72.00	Buy
NAMS NewAmsterdam Pharma	6/17/2025	Initiated Coverage	$19.75	$42.00	Buy
RNA Avidity Biosciences	6/9/2025	Boost Price Target	$33.43	$54.00	Buy
ABBV AbbVie	5/14/2025	Reiterated Rating	$187.95	$205.00	Neutral
KYMR Kymera Therapeutics	5/12/2025	Lower Price Target	$31.92	$44.00	Neutral
PTCT PTC Therapeutics	5/7/2025	Upgrade	$36.19	$40.00	Neutral
NMRA Neumora Therapeutics	4/2/2025	Reiterated Rating	$0.91	$1.00	Underperform
ETNB 89BIO	3/13/2025	Initiated Coverage	$8.35	$25.00	Buy
APGE Apogee Therapeutics	3/13/2025	Initiated Coverage	$38.53	$95.00	Buy
BNTX BioNTech	3/13/2025	Initiated Coverage	$100.31	$145.00	Buy
KNSA Kiniksa Pharmaceuticals International	3/13/2025	Initiated Coverage	$22.50	$40.00	Buy
RNA Avidity Biosciences	3/13/2025	Initiated Coverage	$32.61	$70.00	Buy
KYMR Kymera Therapeutics	3/13/2025	Initiated Coverage	$35.10	$52.00	Buy
MRNA Moderna	3/13/2025	Initiated Coverage	$35.01	$40.00	Neutral
RNA Avidity Biosciences	3/10/2025	Lower Price Target	$30.22	$48.00	Buy
BMRN BioMarin Pharmaceutical	2/20/2025	Boost Price Target	$65.61	$103.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.